Compile Data Set for Download or QSAR
Report error Found 33 Enz. Inhib. hit(s) with all data for entry = 13322
TargetSodium channel protein type 10 subunit alpha(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM779962(Methyl 4-[[6-[2-chloro-3-fluoro-4-(trifluoromethox...)
Affinity DataIC50: 100nMAssay Description:1) To reach the final concentration in each well, 400 nL of each compound was pre-spotted (in neat DMSO) into polypropylene compound plates at 250× d...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
2/3/2026
Entry Details
US Patent

TargetSodium channel protein type 10 subunit alpha(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM779959(Methyl 4-[[2-fluoro-6-[3-fluoro-2-methyl-4-(triflu...)
Affinity DataIC50: 100nMAssay Description:1) To reach the final concentration in each well, 400 nL of each compound was pre-spotted (in neat DMSO) into polypropylene compound plates at 250× d...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
2/3/2026
Entry Details
US Patent

TargetSodium channel protein type 10 subunit alpha(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM779958(Methyl 4-[[6-[3-fluoro-2-methyl-4-(trifluoromethox...)
Affinity DataIC50: 100nMAssay Description:1) To reach the final concentration in each well, 400 nL of each compound was pre-spotted (in neat DMSO) into polypropylene compound plates at 250× d...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
2/3/2026
Entry Details
US Patent

TargetSodium channel protein type 10 subunit alpha(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM779957(Methyl 5-[[2-fluoro-6-[2-methoxy-4-(trifluorometho...)
Affinity DataIC50: 300nMAssay Description:1) To reach the final concentration in each well, 400 nL of each compound was pre-spotted (in neat DMSO) into polypropylene compound plates at 250× d...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
2/3/2026
Entry Details
US Patent

TargetSodium channel protein type 10 subunit alpha(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM779972(US12440481, Compound 30)
Affinity DataIC50: 300nMAssay Description:1) To reach the final concentration in each well, 400 nL of each compound was pre-spotted (in neat DMSO) into polypropylene compound plates at 250× d...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
2/3/2026
Entry Details
US Patent

TargetSodium channel protein type 10 subunit alpha(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM779956(Methyl 5-[[2-fluoro-6-[3-fluoro-2-methoxy-4-(trifl...)
Affinity DataIC50: 300nMAssay Description:1) To reach the final concentration in each well, 400 nL of each compound was pre-spotted (in neat DMSO) into polypropylene compound plates at 250× d...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
2/3/2026
Entry Details
US Patent

TargetSodium channel protein type 10 subunit alpha(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM779953(methyl 5-[[2-fluoro-6-[2-(trideuteriomethoxy)-4-(t...)
Affinity DataIC50: 300nMAssay Description:1) To reach the final concentration in each well, 400 nL of each compound was pre-spotted (in neat DMSO) into polypropylene compound plates at 250× d...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
2/3/2026
Entry Details
US Patent

TargetSodium channel protein type 10 subunit alpha(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM779967(Methyl 4-[[2-hydroxy-6-[2-methoxy-4-(trifluorometh...)
Affinity DataIC50: 300nMAssay Description:1) To reach the final concentration in each well, 400 nL of each compound was pre-spotted (in neat DMSO) into polypropylene compound plates at 250× d...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
2/3/2026
Entry Details
US Patent

TargetSodium channel protein type 10 subunit alpha(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM779948(methyl 4-[[5-fluoro-2-[2-(trideuteriomethoxy)-4-(t...)
Affinity DataIC50: 300nMAssay Description:1) To reach the final concentration in each well, 400 nL of each compound was pre-spotted (in neat DMSO) into polypropylene compound plates at 250× d...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
2/3/2026
Entry Details
US Patent

TargetSodium channel protein type 10 subunit alpha(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM779947(methyl 4-[[2-fluoro-6-[4-(trifluoromethoxy)phenoxy...)
Affinity DataIC50: 300nMAssay Description:1) To reach the final concentration in each well, 400 nL of each compound was pre-spotted (in neat DMSO) into polypropylene compound plates at 250× d...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
2/3/2026
Entry Details
US Patent

TargetSodium channel protein type 10 subunit alpha(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM779946(methyl 4-[[3-cyclopropyl-6-[2-methoxy-4-(trifluoro...)
Affinity DataIC50: 300nMAssay Description:1) To reach the final concentration in each well, 400 nL of each compound was pre-spotted (in neat DMSO) into polypropylene compound plates at 250× d...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
2/3/2026
Entry Details
US Patent

TargetSodium channel protein type 10 subunit alpha(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM779977(US12440481, Compound 35)
Affinity DataIC50: 300nMAssay Description:1) To reach the final concentration in each well, 400 nL of each compound was pre-spotted (in neat DMSO) into polypropylene compound plates at 250× d...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
2/3/2026
Entry Details
US Patent

TargetSodium channel protein type 10 subunit alpha(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM779971(US12440481, Compound 29)
Affinity DataIC50: 750nMAssay Description:1) To reach the final concentration in each well, 400 nL of each compound was pre-spotted (in neat DMSO) into polypropylene compound plates at 250× d...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
2/3/2026
Entry Details
US Patent

TargetSodium channel protein type 10 subunit alpha(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM779950(methyl 4-[[2-[2-(trideuteriomethoxy)-4-(trifluorom...)
Affinity DataIC50: 750nMAssay Description:1) To reach the final concentration in each well, 400 nL of each compound was pre-spotted (in neat DMSO) into polypropylene compound plates at 250× d...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
2/3/2026
Entry Details
US Patent

TargetSodium channel protein type 10 subunit alpha(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM779965(Methyl 2-[[2-fluoro-6-[3-fluoro-2-methoxy-4-(trifl...)
Affinity DataIC50: 750nMAssay Description:1) To reach the final concentration in each well, 400 nL of each compound was pre-spotted (in neat DMSO) into polypropylene compound plates at 250× d...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
2/3/2026
Entry Details
US Patent

TargetSodium channel protein type 10 subunit alpha(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM779960(Methyl 4-[[6-(3,4-difluoro-2-methyl-phenoxy)-2-met...)
Affinity DataIC50: 750nMAssay Description:1) To reach the final concentration in each well, 400 nL of each compound was pre-spotted (in neat DMSO) into polypropylene compound plates at 250× d...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
2/3/2026
Entry Details
US Patent

TargetSodium channel protein type 10 subunit alpha(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM779955(methyl 5-[[2-fluoro-6-[4-(trifluoromethoxy)phenoxy...)
Affinity DataIC50: 1.00E+3nMAssay Description:1) To reach the final concentration in each well, 400 nL of each compound was pre-spotted (in neat DMSO) into polypropylene compound plates at 250× d...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
2/3/2026
Entry Details
US Patent

TargetSodium channel protein type 10 subunit alpha(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM779954(methyl 5-[[2-[2-(trideuteriomethoxy)-4-(trifluorom...)
Affinity DataIC50: 1.00E+3nMAssay Description:1) To reach the final concentration in each well, 400 nL of each compound was pre-spotted (in neat DMSO) into polypropylene compound plates at 250× d...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
2/3/2026
Entry Details
US Patent

TargetSodium channel protein type 10 subunit alpha(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM779952(methyl 5-[[2-fluoro-6-(4-fluoro-2-methoxy-phenoxy)...)
Affinity DataIC50: 1.00E+3nMAssay Description:1) To reach the final concentration in each well, 400 nL of each compound was pre-spotted (in neat DMSO) into polypropylene compound plates at 250× d...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
2/3/2026
Entry Details
US Patent

TargetSodium channel protein type 10 subunit alpha(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM779951(tert-butyl N-[4-[[2-[2-(trideuteriomethoxy)-4-(tri...)
Affinity DataIC50: 1.00E+3nMAssay Description:1) To reach the final concentration in each well, 400 nL of each compound was pre-spotted (in neat DMSO) into polypropylene compound plates at 250× d...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
2/3/2026
Entry Details
US Patent

TargetSodium channel protein type 10 subunit alpha(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM779964(Methyl 4-[[6-[2-chloro-4-(trifluoromethoxy)phenoxy...)
Affinity DataIC50: 1.00E+3nMAssay Description:1) To reach the final concentration in each well, 400 nL of each compound was pre-spotted (in neat DMSO) into polypropylene compound plates at 250× d...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
2/3/2026
Entry Details
US Patent

TargetSodium channel protein type 10 subunit alpha(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM779963(Methyl 4-[[2-fluoro-6-[2-methoxy-4-(trifluorometho...)
Affinity DataIC50: 1.00E+3nMAssay Description:1) To reach the final concentration in each well, 400 nL of each compound was pre-spotted (in neat DMSO) into polypropylene compound plates at 250× d...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
2/3/2026
Entry Details
US Patent

TargetSodium channel protein type 10 subunit alpha(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM779961(Methyl 4-[[6-(3,4-difluoro-2-methyl-phenoxy)-2-met...)
Affinity DataIC50: 1.00E+3nMAssay Description:1) To reach the final concentration in each well, 400 nL of each compound was pre-spotted (in neat DMSO) into polypropylene compound plates at 250× d...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
2/3/2026
Entry Details
US Patent

TargetSodium channel protein type 10 subunit alpha(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM779973(US12440481, Compound 31)
Affinity DataIC50: 1.00E+3nMAssay Description:1) To reach the final concentration in each well, 400 nL of each compound was pre-spotted (in neat DMSO) into polypropylene compound plates at 250× d...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
2/3/2026
Entry Details
US Patent

TargetSodium channel protein type 10 subunit alpha(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM779970(US12440481, Compound 28)
Affinity DataIC50: 1.00E+3nMAssay Description:1) To reach the final concentration in each well, 400 nL of each compound was pre-spotted (in neat DMSO) into polypropylene compound plates at 250× d...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
2/3/2026
Entry Details
US Patent

TargetSodium channel protein type 10 subunit alpha(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM779969(US12440481, Compound 27)
Affinity DataIC50: 1.00E+3nMAssay Description:1) To reach the final concentration in each well, 400 nL of each compound was pre-spotted (in neat DMSO) into polypropylene compound plates at 250× d...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
2/3/2026
Entry Details
US Patent

TargetSodium channel protein type 10 subunit alpha(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM779968(US12440481, Compound 26)
Affinity DataIC50: 1.00E+3nMAssay Description:1) To reach the final concentration in each well, 400 nL of each compound was pre-spotted (in neat DMSO) into polypropylene compound plates at 250× d...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
2/3/2026
Entry Details
US Patent

TargetSodium channel protein type 10 subunit alpha(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM779966(Methyl 2-[[6-[3-fluoro-2-methoxy-4-(trifluorometho...)
Affinity DataIC50: 1.00E+3nMAssay Description:1) To reach the final concentration in each well, 400 nL of each compound was pre-spotted (in neat DMSO) into polypropylene compound plates at 250× d...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
2/3/2026
Entry Details
US Patent

TargetSodium channel protein type 10 subunit alpha(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM779949(tert-butyl N-[4-[[5-fluoro-2-[2-(trideuteriomethox...)
Affinity DataIC50: 1.00E+3nMAssay Description:1) To reach the final concentration in each well, 400 nL of each compound was pre-spotted (in neat DMSO) into polypropylene compound plates at 250× d...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
2/3/2026
Entry Details
US Patent

TargetSodium channel protein type 10 subunit alpha(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM779945(Methyl 5-[[5-fluoro-2-[2-(trideuteriomethoxy)-4-(t...)
Affinity DataIC50: 1.00E+3nMAssay Description:1) To reach the final concentration in each well, 400 nL of each compound was pre-spotted (in neat DMSO) into polypropylene compound plates at 250× d...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
2/3/2026
Entry Details
US Patent

TargetSodium channel protein type 10 subunit alpha(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM779976(US12440481, Compound 34)
Affinity DataIC50: 1.00E+3nMAssay Description:1) To reach the final concentration in each well, 400 nL of each compound was pre-spotted (in neat DMSO) into polypropylene compound plates at 250× d...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
2/3/2026
Entry Details
US Patent

TargetSodium channel protein type 10 subunit alpha(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM779975(US12440481, Compound 33)
Affinity DataIC50: 1.00E+3nMAssay Description:1) To reach the final concentration in each well, 400 nL of each compound was pre-spotted (in neat DMSO) into polypropylene compound plates at 250× d...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
2/3/2026
Entry Details
US Patent

TargetSodium channel protein type 10 subunit alpha(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM779974(US12440481, Compound 32)
Affinity DataIC50: 1.00E+3nMAssay Description:1) To reach the final concentration in each well, 400 nL of each compound was pre-spotted (in neat DMSO) into polypropylene compound plates at 250× d...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
2/3/2026
Entry Details
US Patent